Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idio… Read more
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.068x
Based on the latest financial reports, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a cash flow conversion efficiency ratio of -0.068x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.20 Million) by net assets ($180.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Contineum Therapeutics, Inc. Class A Common Stock - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Contineum Therapeutics, Inc. Class A Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Contineum Therapeutics, Inc. Class A Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Contineum Therapeutics, Inc. Class A Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
E&R Engineering
TWO:8027
|
0.062x |
|
International Personal Finance plc
PINK:IPFPF
|
0.010x |
|
Opple Lighting Co Ltd
SHG:603515
|
1.058x |
|
Yuanta Securities Korea Co Ltd Preference Shares
KO:003475
|
-0.033x |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
0.002x |
|
Liuzhou Liangmianzhen Co Ltd
SHG:600249
|
0.015x |
|
Dong Fang Offshore Co., Ltd.
TW:7786
|
0.293x |
|
Real Matters Inc
PINK:RLLMF
|
0.043x |
Annual Cash Flow Conversion Efficiency for Contineum Therapeutics, Inc. Class A Common Stock (2021–2024)
The table below shows the annual cash flow conversion efficiency of Contineum Therapeutics, Inc. Class A Common Stock from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $198.07 Million | $-32.84 Million | -0.166x | +41.78% |
| 2023-12-31 | $-67.94 Million | $19.35 Million | -0.285x | +44.41% |
| 2022-12-31 | $39.27 Million | $-20.12 Million | -0.512x | -20.14% |
| 2021-12-31 | $61.59 Million | $-26.27 Million | -0.426x | -- |